嵌合抗原受体
细胞因子释放综合征
医学
免疫学
多发性骨髓瘤
抗原
抗体
低丙种球蛋白血症
临床试验
中性粒细胞减少症
T细胞
免疫系统
内科学
化疗
作者
Meera Mohan,Rajshekhar Chakraborty,Susan Bal,Anoma Nellore,Muhamed Baljevic,Anita D’Souza,Peter G. Pappas,Jesús G. Berdeja,Natalie S. Callander,Luciano J. Costa
摘要
Summary Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However, their use is associated with a significant risk of severe infections, which can be attributed to various factors such as hypogammaglobulinemia, neutropenia, lymphopenia, T‐cell exhaustion, cytokine‐release syndrome and immune‐effector cell‐associated neurotoxicity syndrome. As these therapies have been recently approved by regulatory agencies, it is crucial to establish practical guidelines for infection monitoring and prevention until robust data from prospective clinical trials become available. To address this issue, a panel of experienced investigators from the Academic Consortium to Overcome Multiple Myeloma through Innovative Trials (COMMIT) developed consensus recommendations for mitigating infections associated with CAR T‐cell and bispecific antibody therapies in MM patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI